MedTrace Logo

Lapatinib and Bevacizumab for Metastatic Breast Cancer

NCT00444535 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2021-10-25

Study results available
· View outcomes & findings →

Summary

This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.

Conditions

  • Neoplasms, Breast

Interventions

DRUG

lapatinib

1500 mg oral lapatinib (once daily)

DRUG

bevacizumab

10 mg/kg intravenous bevacizumab (every two weeks)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-27
Primary Completion
2008-07-22
Completion
2020-06-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00444535 on ClinicalTrials.gov